Received Nov 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
User posted they experienced insomnia and cold shaking sweats after the first dose of SHINGRIX.; User posted they experienced insomnia and cold shaking sweats after the first dose of SHINGRIX.; Had only minor aches; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of cold sweat in a patient who received Herpes zoster (Shingrix) for prophylaxis. The patient received the 1st dose of Shingrix. After receiving Shingrix, the patient experienced cold sweat (Verbatim: User posted they experienced insomnia and cold shaking sweats after the first dose of SHINGRIX.), insomnia (Verbatim: User posted they experienced insomnia and cold shaking sweats after the first dose of SHINGRIX.) and ache (Verbatim: Had only minor aches). The outcome of the cold sweat and insomnia were resolved (duration 1 day) and the outcome of the ache was not reported (duration 1 day). It was unknown if the reporter considered the cold sweat, insomnia and ache to be related to Shingrix. It was unknown if the company considered the cold sweat, insomnia and ache to be related to Shingrix. Linked case(s) involving the same patient: US2025AMR140659 Additional Information: GSK Receipt Date: 26-OCT-2025 The reporter stated that the patient got first shot, caused insomnia and cold shaking sweats and resolved next morning. The reporter also mentioned that the patient had minor aches. The batch number was not provided, and we are unable to contact the reporter. For tolerance to 2nd dose, refer case US2025AMR140659.